Frequency Therapeutics has once again updated the official Study Record of its Phase 2a clinical trial of FX-322 in Adults With Stable Sensorineural Hearing Loss.
The update – which includes a new clinical trial site in Austin, Texas – was posted to ClinicalTrials.gov on April 10, 2020.
No Slowdown Due to COVID-19?
It looks like the FX-322 trial is still moving forward as expected, running on schedule.
Usually, a small change to a study record would not seem like such big news.
However, in the context of COVID-19, it is noteworthy. And uplifting! Why?
Consider this: while many clinical trials across the world are experiencing massive slowdowns and stoppages due to COVID-19, the FX-322 Phase 2a trial is expanding its presence to yet another location in the United States. Expanding!
That is not to say the trial has not been affected by COVID-19. For example, patient recruitment efforts and other logistics have probably become more challenging.
However, despite all that is happening, what we see with this update is more activity and signs of life. Things are happening. Plus, we have proof that the study is not paused or stopped. In fact, there is no sign of any delay at all…
FULL SPEED AHEAD!
The estimated study completion date (September 30, 2020) remains unchanged. Repeat: the estimated completion date of the FX-322 trial has NOT been pushed back despite the impact of COVID-19, according to the latest study record.
Small update, big news.
Link to official study page:
Get email updates (while you still can)
The Hearing Loss Treatment Report newsletter will be starting soon. It is a once-weekly email update that will be sent out every Saturday. It is free, your email address will remain private and not be shared with anyone, and you can unsubscribe at any time with a single click.
Click here to subscribe to email updates
(Note: If you have already submitted your email and added your name to the updates list, you are all set. You do not need to sign up again! You’re on the list and will receive updates as soon as they begin.)